Prevention of catecholaminergic oxidative toxicity by 4-hydroxy-2,2,6,6- tetramethylpiperidine-1-oxyl and its recycling complex with polynitroxylated albumin, TEMPOL/PNA

Brain Research

Volumn 1012, Issue 1-2, 2004, Pages 13-21

  Weinberg, Ariella ^a   Nylander, Karen D ^a   Yan, Chaohua ^a   Ma, Li ^b   Hsia, Carleton J C ^b   Tyurin, Vladimir A ^c   Kagan, Valerian E ^c   Schor, Nina F ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b Synzyme Technologies Inc   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 4 hydroxy 2,2,6,6 tetramethylpiperidine 1 oxyl; 6 OHDA; Catecholaminergic oxidative toxicity; Dopamine; MPTP; PNA; polynitroxylated albumin; Reactive oxygen species; reactive oxygen species; ROS; TEMPOL

Indexed keywords

ALBUMIN; ANTIOXIDANT; CATECHOLAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOPAMINE; POLYNITROXYLATED ALBUMIN; REACTIVE OXYGEN METABOLITE; TEMPOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL STRAIN; CONTROLLED STUDY; CYTOPLASM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL MODEL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RAT; TIME; TOXICITY;

ALBUMINS; ANIMALS; APOPTOSIS; CATECHOLAMINES; CYCLIC N-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NITROGEN OXIDES; OXIDANTS; OXIDATIVE STRESS; OXIDOPAMINE; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES; SERUM ALBUMIN; SPIN LABELS;

EID: 2442449016     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.03.048     Document Type: Article

References (43)

1. Aminoff M.J. Treatment of Parkinson's disease. West. J. Med. 161:1994;303-308
2. Apte M., Macallister D.L., Swartz H.M. Reduction of nitroxide in whole blood, erythrocytes and plasma. Curr. Top. Biophys. 18:1994;81-91
3. Bonnet A.M., Houeto J.L. Pathophysiology of Parkinson's disease. Biomed. Pharmacother. 53:1999;117-121
4. Borisenko G.G., Kagan V.E., Hsia C.J.C., Schor N.F. Interaction between 6-hydroxydopamine and transferrin: "Let my iron go" Biochemistry. 39:2000;3392-3400
5. Chateauneuf J., Lusztyk J., Ingold K.U. Absolute rate constants for the reactions of some carbon-centered radicals with 2, 2, 6, 6- tetramethylpiperidine-N-oxyl. J. Org. Chem. 53:1998;1629-1632
6. Chelmicka-Szorc E., Arnason B.G.W. Effect of 6-hydroxydopamine on tumor growth. Cancer Res. 36:1976;2382-2384
7. Cohen G., Heikkila R.E. The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249:1974;2447-2452
8. Hahn S.M., Tochner Z., Krishna C.M., Glass J., Wilson L., Samuni A., Sprague M., Venzon D., Glatstein E., Mitchell J.B. TEMPOL, a stable free radical, is a novel murine radiation protector. Cancer Res. 52:1992;1750-1753
9. Han J., Cheng F.C., Yang Z., Dryhurst G. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J. Neurochem. 73:1999;1683-1695
10. Hartsell T.L., Hinman L.M., Hamann P.R., Schor N.F. Determinants of the response of neuroblastoma cells to DNA damage: the roles of pre-treatment cell morphology and chemical nature of the damage. J. Pharmacol. Exp. Ther. 277:1996;1158-1166
11. Hastings T.G., Zigmond M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural Transm., Suppl. 49:1997;103-110
12. Hastings T.G., Lewis D.A., Zigmond M.J. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv. Exp. Med. Biol. 387:1996;97-106
13. Hubel C.A., Kagan V.E., Kisin E.R., McLaughlin M.K., Roberts J.M. Increased ascorbate radical formation and ascorbate depletion in plasma from women with preeclampsia: implications for oxidative stress. Free Radic. Biol. Med. 23:1997;596-609
14. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47(6 Suppl. 3):1996;S161-S170
15. Kentner R., Safar P., Behringer W., Wu X., Kagan V.E., Tyurina Y.Y., Henchir J., Ma L., Hsia C.J., Tisherman S.A. Early antioxidant therapy with Tempol during hemorrhagic shock increases survival in rats. J. Trauma. 53:2002 (Nov);968-977
16. Kitazawa M., Wagner J.R., Kirby M.L., Anantharam V., Kanthasamy A.G. Oxidative stress and mitochondrial-mediated apoptosis in dopaminergic cells exposed to methylcyclopentadienyl manganese tricarbonyl. J. Pharmacol. Exp. Ther. 302:2002;26-35
17. Kocherginsky N., Swartz H.M. Nitroxide Spin Label. 1995;114-172 CRC Press, Boca Raton
18. Krishna M.C., Samuni A. Nitroxides as antioxidants. Methods Enzymol. 234:1994;580-589
19. Krishna M.C., Grahame D.A., Samuni A., Mitchell J.B., Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc. Natl. Acad. Sci. U. S. A. 89:1992;5537-5541
20. Kuppusamy P., Wang P., Zweier J.L., Krishna M.C., Mitchell J.B., Ma L., Trimble C.E., Hsia C.J. Electron paramagnetic resonance imaging of rat heart with nitroxide and polynitroxyl-albumin. Biochemistry. 35:1996;7051-7057
21. Liang Y., Nylander K.D., Schor N.F. Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2. Mol. Pharmacol. 61:2002;142-149
22. Luo Y., Roth G.S. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid. Redox Signal. 2:2000;449-460
23. Malmfors T., Sachs C. Degeneration of adrenergic nerves produced by 6-hydroxydopamine. Eur. J. Pharmacol. 3:1968;89-92
24. Martinez M., Martinez N., Hernandez A.I., Ferrandiz M.L. Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci. 64:1999;1253-1257
25. Merad-Boudia M., Nicole A., Santiard-Baron D., Sallie C., Ceballos-Picot I. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem. Pharmacol. 56:1998;645-655
26. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44(Suppl. 1):1998;S167-S174
27. Oliveira M.T., Rego A.C., Morgadinho M.T., Macedo T.R., Oliveira C.R. Toxic effects of opioid and stimulant drugs on undifferentiated PC12 cells. Ann. N.Y. Acad. Sci. 965:2002;487-496
28. Purpura P., Westman L., Will P., Eidelman A., Kagan V.E., Osipov A.N., Schor N.F. Adjunctive treatment of murine neuroblastoma with 6-hydroxydopamine and Tempol. Cancer Res. 56:1996;2336-2342
29. Samuni A., Mitchell J.B., DeGraff W., Krishna C.M., Samuni U., Russo A. Nitroxide SOD-mimics: modes of action. Free Radic. Res. Commun. 12/13:1991;187-194
30. Samuni A., Winkelsberg D., Pinson A., Hahn S.M., Mitchell J.B., Russo A. Nitroxide stable radicals protect beating cardiomyocytes against oxidative damage. J. Clin. Invest. 87:1991;1526-1530
31. Sawada H., Ibi M., Khara T., Urushitani M., Akaike A., Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J. Neurosci. Res. 54:1998;707-719
32. Schor N.F. Adjunctive use of Ethiofos (WR-2721) with free radical-generating chemotherapeutic agents in mice: new caveats for therapy. Cancer Res. 47:1987;5411-5414
33. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Ann. Neurol. 44(3 Suppl. 1):1998;S160-S166
34. Shults C.W., Haas R.H., Beal M.F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. BioFactors. 9:1999;267-272
35. Simon D.K., Standaert D.G. Neuroprotective therapies. Med. Clin. North Am. 83:1999;509-523
36. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71:1998;2112-2122
37. Thoenen H., Tranzer J.P. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol. 261:1968;271-288
38. Yan C., Liang Y., Nylander K.D., Wang J., Rudavsky R., Saragovi H.U., Schor N.F. The p75/TrkA ratio determines the mechanism of the antiapoptotic effect of NGF. Mol. Pharmacol. 61:2002;710-719
39. Yan C., Liang Y., Nylander K.D., Schor N.F. TrkA as a life-and-death receptor: receptor dose as a mediator of function. Cancer Res. 62:2002;4867-4875
40. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.-I., Jones D.P., Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1997;1129-1132
41. waf1/cip1, and erythropoietin. J. Neurosci. 19:1999;9821-9830
42. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154:1999;1423-1429
43. Zhang S., Li H., Ma L., Trimble C.E., Kuppasamy P., Hsia C.J., Carden D.L. Polynitroxyl-albumin (PNA) plus TEMPOL attenuate lung capillary leak elicited by prolonged intestinal ischemia and reperfusion. Free Radic. Biol. Med. 29:2000;42-50